Agenus (NASDAQ: AGEN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Agenus Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Agenus Company Info
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
News & Analysis
Agenus presented data this week on a combination therapy.
The company's shares climbed with help from insider buying.
The company has a promising colon cancer therapy.
The company reported encouraging results from an early study of its experimental colorectal cancer combo therapy.
An optimistic analyst upgrade is powering the biotech's shares higher today.
A long-awaited regulatory event sent the biotech's shares on a roller-coaster ride last year.
The biotech delivers better-than-expected Q3 results.
The company's experimental anti-PD1 drug hit a wall.
AGEN earnings call for the period ending December 31, 2022.
AGEN earnings call for the period ending September 30, 2022.
AGEN earnings call for the period ending June 30, 2022.
AGEN earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.